BrightGene Begin Period Cash Flow vs Change In Cash Analysis

688166 Stock

30.14 1.06 3.40%

BrightGene Bio financial indicator trend analysis is way more than just evaluating BrightGene Bio Medical prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether BrightGene Bio Medical is a good investment. Please check the relationship between BrightGene Bio Begin Period Cash Flow and its Change In Cash accounts. Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

Begin Period Cash Flow vs Change In Cash

Begin Period Cash Flow vs Change In Cash Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of BrightGene Bio Medical Begin Period Cash Flow account and Change In Cash. At this time, the significance of the direction appears to have weak relationship.

The correlation between BrightGene Bio's Begin Period Cash Flow and Change In Cash is 0.35. Overlapping area represents the amount of variation of Begin Period Cash Flow that can explain the historical movement of Change In Cash in the same time period over historical financial statements of BrightGene Bio Medical, assuming nothing else is changed. The correlation between historical values of BrightGene Bio's Begin Period Cash Flow and Change In Cash is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Begin Period Cash Flow of BrightGene Bio Medical are associated (or correlated) with its Change In Cash. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Change In Cash has no effect on the direction of Begin Period Cash Flow i.e., BrightGene Bio's Begin Period Cash Flow and Change In Cash go up and down completely randomly.

Correlation Coefficient

0.35

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Change In Cash

Most indicators from BrightGene Bio's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into BrightGene Bio Medical current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

As of February 5, 2025, Tax Provision is expected to decline to about 14.9 M. In addition to that, Selling General Administrative is expected to decline to about 73.5 M

	2022	2023	2024	2025 (projected)
Gross Profit	641.0M	658.1M	756.8M	438.0M
Total Revenue	1.0B	1.2B	1.4B	751.2M

Gross Profit Total Revenue

BrightGene Bio fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Net Receivables	Short Term Investments	Inventory	Other Current Assets	Total Liab	Deferred Long Term Liab	Short Long Term Debt	Total Current Assets	Intangible Assets	Common Stock	Property Plant Equipment	Other Liab	Common Stock Shares Outstanding	Net Invested Capital	Net Working Capital
Total Assets		-0.5	0.98	0.9	0.88	1.0	0.98	0.97	0.99	0.56	0.98	0.85	0.01	0.99	0.85	0.98	0.76	0.71	0.9	0.97	0.8	0.99	0.75	0.83	1.0	0.83
Other Current Liab	-0.5		-0.48	-0.52	-0.49	-0.52	-0.43	-0.4	-0.51	-0.25	-0.46	-0.48	-0.16	-0.56	-0.23	-0.45	-0.43	0.01	-0.44	-0.52	-0.54	-0.45	-0.4	-0.55	-0.47	-0.35
Total Current Liabilities	0.98	-0.48		0.84	0.81	0.97	0.98	0.92	0.99	0.52	0.96	0.8	-0.15	0.96	0.84	1.0	0.71	0.65	0.84	0.98	0.72	0.99	0.64	0.75	0.98	0.73
Total Stockholder Equity	0.9	-0.52	0.84		1.0	0.92	0.87	0.9	0.87	0.67	0.88	0.93	0.22	0.9	0.88	0.84	0.86	0.72	0.99	0.87	0.94	0.87	0.89	0.94	0.9	0.92
Net Tangible Assets	0.88	-0.49	0.81	1.0		0.9	0.86	0.88	0.85	0.68	0.86	0.94	0.24	0.87	0.88	0.81	0.86	0.74	0.98	0.86	0.95	0.85	0.9	0.95	0.88	0.92
Retained Earnings	1.0	-0.52	0.97	0.92	0.9		0.98	0.95	0.99	0.61	0.97	0.88	0.06	0.99	0.86	0.97	0.8	0.72	0.91	0.98	0.83	0.98	0.79	0.86	0.99	0.83
Accounts Payable	0.98	-0.43	0.98	0.87	0.86	0.98		0.92	0.98	0.52	0.94	0.89	-0.12	0.94	0.91	0.97	0.72	0.77	0.87	0.98	0.78	0.99	0.71	0.81	0.98	0.76
Cash	0.97	-0.4	0.92	0.9	0.88	0.95	0.92		0.94	0.55	0.95	0.79	0.13	0.95	0.81	0.94	0.73	0.74	0.93	0.89	0.81	0.94	0.77	0.83	0.97	0.92
Non Current Assets Total	0.99	-0.51	0.99	0.87	0.85	0.99	0.98	0.94		0.54	0.97	0.83	-0.06	0.98	0.85	0.99	0.73	0.68	0.87	0.98	0.76	1.0	0.7	0.79	0.99	0.77
Non Currrent Assets Other	0.56	-0.25	0.52	0.67	0.68	0.61	0.52	0.55	0.54		0.69	0.54	0.34	0.63	0.59	0.49	0.9	0.48	0.63	0.62	0.72	0.51	0.63	0.72	0.57	0.61
Other Assets	0.98	-0.46	0.96	0.88	0.86	0.97	0.94	0.95	0.97	0.69		0.79	0.05	0.98	0.84	0.96	0.81	0.69	0.88	0.96	0.79	0.96	0.71	0.82	0.98	0.81
Net Receivables	0.85	-0.48	0.8	0.93	0.94	0.88	0.89	0.79	0.83	0.54	0.79		0.08	0.82	0.91	0.78	0.78	0.8	0.89	0.87	0.9	0.85	0.86	0.9	0.85	0.78
Short Term Investments	0.01	-0.16	-0.15	0.22	0.24	0.06	-0.12	0.13	-0.06	0.34	0.05	0.08		0.1	-0.11	-0.12	0.26	0.15	0.19	-0.07	0.26	-0.08	0.46	0.25	0.01	0.34
Inventory	0.99	-0.56	0.96	0.9	0.87	0.99	0.94	0.95	0.98	0.63	0.98	0.82	0.1		0.79	0.96	0.8	0.65	0.89	0.96	0.81	0.97	0.77	0.84	0.98	0.82
Other Current Assets	0.85	-0.23	0.84	0.88	0.88	0.86	0.91	0.81	0.85	0.59	0.84	0.91	-0.11	0.79		0.84	0.73	0.86	0.88	0.88	0.8	0.88	0.69	0.8	0.86	0.74
Total Liab	0.98	-0.45	1.0	0.84	0.81	0.97	0.97	0.94	0.99	0.49	0.96	0.78	-0.12	0.96	0.84		0.68	0.66	0.85	0.96	0.7	0.99	0.64	0.73	0.98	0.76
Deferred Long Term Liab	0.76	-0.43	0.71	0.86	0.86	0.8	0.72	0.73	0.73	0.9	0.81	0.78	0.26	0.8	0.73	0.68		0.56	0.82	0.79	0.89	0.71	0.85	0.89	0.77	0.78
Short Long Term Debt	0.71	0.01	0.65	0.72	0.74	0.72	0.77	0.74	0.68	0.48	0.69	0.8	0.15	0.65	0.86	0.66	0.56		0.73	0.7	0.68	0.73	0.68	0.69	0.73	0.69
Total Current Assets	0.9	-0.44	0.84	0.99	0.98	0.91	0.87	0.93	0.87	0.63	0.88	0.89	0.19	0.89	0.88	0.85	0.82	0.73		0.85	0.91	0.87	0.85	0.91	0.91	0.95
Intangible Assets	0.97	-0.52	0.98	0.87	0.86	0.98	0.98	0.89	0.98	0.62	0.96	0.87	-0.07	0.96	0.88	0.96	0.79	0.7	0.85		0.79	0.98	0.71	0.82	0.97	0.73
Common Stock	0.8	-0.54	0.72	0.94	0.95	0.83	0.78	0.81	0.76	0.72	0.79	0.9	0.26	0.81	0.8	0.7	0.89	0.68	0.91	0.79		0.75	0.88	1.0	0.81	0.89
Property Plant Equipment	0.99	-0.45	0.99	0.87	0.85	0.98	0.99	0.94	1.0	0.51	0.96	0.85	-0.08	0.97	0.88	0.99	0.71	0.73	0.87	0.98	0.75		0.69	0.78	0.99	0.77
Other Liab	0.75	-0.4	0.64	0.89	0.9	0.79	0.71	0.77	0.7	0.63	0.71	0.86	0.46	0.77	0.69	0.64	0.85	0.68	0.85	0.71	0.88	0.69		0.88	0.75	0.86
Common Stock Shares Outstanding	0.83	-0.55	0.75	0.94	0.95	0.86	0.81	0.83	0.79	0.72	0.82	0.9	0.25	0.84	0.8	0.73	0.89	0.69	0.91	0.82	1.0	0.78	0.88		0.83	0.89
Net Invested Capital	1.0	-0.47	0.98	0.9	0.88	0.99	0.98	0.97	0.99	0.57	0.98	0.85	0.01	0.98	0.86	0.98	0.77	0.73	0.91	0.97	0.81	0.99	0.75	0.83		0.84
Net Working Capital	0.83	-0.35	0.73	0.92	0.92	0.83	0.76	0.92	0.77	0.61	0.81	0.78	0.34	0.82	0.74	0.76	0.78	0.69	0.95	0.73	0.89	0.77	0.86	0.89	0.84

Click cells to compare fundamentals

BrightGene Bio Account Relationship Matchups

BrightGene Bio fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	1.8B	3.0B	4.7B	5.0B	5.8B	6.1B
Other Current Liab	32.0M	25.9M	50.7M	20.1M	18.1M	26.6M
Total Current Liabilities	291.7M	583.1M	811.5M	922.2M	1.1B	1.1B
Total Stockholder Equity	1.4B	1.7B	2.2B	2.4B	2.7B	1.4B
Net Tangible Assets	1.3B	1.4B	1.6B	2.1B	2.4B	1.2B
Retained Earnings	345.5M	555.1M	743.4M	830.4M	955.0M	1.0B
Accounts Payable	79.6M	211.9M	252.2M	228.2M	262.4M	275.5M
Cash	339.5M	336.8M	1.2B	998.0M	1.1B	1.2B
Non Current Assets Total	881.4M	2.0B	2.7B	3.2B	3.7B	3.9B
Non Currrent Assets Other	628.5M	115.9M	300.9M	233.3M	268.3M	184.6M
Other Assets	56.8M	223.3M	161.5M	351.7M	404.5M	424.7M
Net Receivables	177.3M	373.3M	302.8M	283.0M	325.4M	224.4M
Non Current Liabilities Total	103.5M	644.9M	1.6B	1.7B	1.9B	2.0B
Inventory	203.2M	200.1M	280.4M	344.6M	396.3M	416.1M
Other Current Assets	39.6M	73.3M	95.4M	65.2M	75.0M	49.4M
Total Liab	395.2M	1.2B	2.4B	2.6B	3.0B	3.2B
Deferred Long Term Liab	22.9M	33.0M	25.8M	26.9M	30.9M	26.2M
Total Current Assets	946.4M	993.0M	1.9B	1.8B	2.1B	1.1B
Intangible Assets	48.8M	80.8M	81.6M	93.7M	107.7M	113.1M
Property Plant Equipment	244.7M	452.5M	1.4B	2.1B	2.4B	2.5B
Net Invested Capital	1.7B	2.6B	4.2B	4.1B	4.8B	5.0B
Net Working Capital	654.7M	409.9M	1.1B	917.5M	1.1B	745.5M
Other Stockholder Equity	(7.2M)	(24.8M)	(25.8M)	17.8M	20.4M	21.5M
Property Plant And Equipment Net	452.5M	1.4B	2.1B	2.5B	2.9B	1.5B
Property Plant And Equipment Gross	577.3M	1.5B	2.1B	2.7B	3.1B	1.6B

Currently Active Assets on Macroaxis

EBR	Centrais Electricas Brasileiras
HE	Hawaiian Electric Industries
VFC	VF Corporation
BVHMF	Vistry Group PLC
S	SentinelOne

Other Information on Investing in BrightGene Stock

Balance Sheet is a snapshot of the financial position of BrightGene Bio Medical at a specified time, usually calculated after every quarter, six months, or one year. BrightGene Bio Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of BrightGene Bio and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which BrightGene currently owns. An asset can also be divided into two categories, current and non-current.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

BrightGene Begin Period Cash Flow vs Change In Cash Analysis

Begin Period Cash Flow vs Change In Cash

Begin Period Cash Flow vs Change In Cash Correlation Analysis

Correlation Coefficient

Begin Period Cash Flow

Change In Cash

BrightGene Bio fundamental ratios Correlations

BrightGene Bio Account Relationship Matchups

High Positive Relationship

High Negative Relationship

BrightGene Bio fundamental ratios Accounts

Currently Active Assets on Macroaxis

Other Information on Investing in BrightGene Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Retained Earnings	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Assets
Total Liab	+ 1.0	Total Current Liabilities
Net Tangible Assets	+ 1.0	Total Stockholder Equity
Property Plant Equipment	+ 1.0	Non Current Assets Total
Common Stock Shares Outstanding	+ 1.0	Common Stock

Inventory	- 0.56	Other Current Liab
Common Stock Shares Outstanding	- 0.55	Other Current Liab
Common Stock	- 0.54	Other Current Liab
Intangible Assets	- 0.52	Other Current Liab
Retained Earnings	- 0.52	Other Current Liab
Total Stockholder Equity	- 0.52	Other Current Liab